WO2004005540A3 - Utilisations de substances qui se lient a ngal pour le diagnostic et le traitement de maladies cancereuses - Google Patents
Utilisations de substances qui se lient a ngal pour le diagnostic et le traitement de maladies cancereuses Download PDFInfo
- Publication number
- WO2004005540A3 WO2004005540A3 PCT/DE2003/001986 DE0301986W WO2004005540A3 WO 2004005540 A3 WO2004005540 A3 WO 2004005540A3 DE 0301986 W DE0301986 W DE 0301986W WO 2004005540 A3 WO2004005540 A3 WO 2004005540A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ngal
- diagnosis
- treatment
- binding substances
- cancer diseases
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003245858A AU2003245858A1 (en) | 2002-07-02 | 2003-06-12 | Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10230631.1 | 2002-07-02 | ||
DE10230631A DE10230631A1 (de) | 2002-07-02 | 2002-07-02 | Verwendungen von an Ngal bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004005540A2 WO2004005540A2 (fr) | 2004-01-15 |
WO2004005540A3 true WO2004005540A3 (fr) | 2004-09-16 |
Family
ID=29761726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2003/001986 WO2004005540A2 (fr) | 2002-07-02 | 2003-06-12 | Utilisations de substances qui se lient a ngal pour le diagnostic et le traitement de maladies cancereuses |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2003245858A1 (fr) |
DE (1) | DE10230631A1 (fr) |
WO (1) | WO2004005540A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006086638A2 (fr) * | 2005-02-10 | 2006-08-17 | Board Of Regents, The University Of Texas System | Ciblage d'un facteur pro-apoptotique secrete a des fins de carcinotherapie |
WO2008030370A1 (fr) * | 2006-09-05 | 2008-03-13 | Beth Israel Deaconess Medical Center, Inc. | Utilisation de la lipocaline 2 dans la régulation de la sensibilité à l'insuline |
US8846036B2 (en) | 2007-10-19 | 2014-09-30 | Abbott Laboratories | Antibodies that bind to mammalian NGAL and uses thereof |
JP2011501673A (ja) * | 2007-10-19 | 2011-01-13 | アボット・ラボラトリーズ | グリコシル化された哺乳動物ngal及びその使用 |
CA2742291A1 (fr) | 2008-11-05 | 2010-05-14 | Abbott Laboratories | Isoformes proteiques de lipocaline associee a une gelatinase neutrophile (ngal) enrichies a partir d'urine et de cellules d'ovaire de hamster chinois recombinantes (cho), et compositions apparentees, anticorps et procedes d'enrichissement, d'analyse et d'utilisation |
GB201016852D0 (en) * | 2010-10-07 | 2010-11-17 | Univ York | Cell differentiation |
CN109709340B (zh) * | 2018-12-29 | 2022-02-11 | 江苏众红生物工程创药研究院有限公司 | 人中性粒细胞明胶酶相关脂质运载蛋白定量检测卡及其临床应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998030907A1 (fr) * | 1997-01-06 | 1998-07-16 | Wisconsin Alumni Research Foundation | Dosage de detection immunohistochimique pour la determination de l'etat de proliferation d'un cancer |
WO1999053040A2 (fr) * | 1998-04-09 | 1999-10-21 | Metagen Gesellschaft Für Genomforschung Mbh | Sequences d'acide nucleique humain provenant de tissu de tumeur ovarienne |
WO2002024866A2 (fr) * | 2000-09-21 | 2002-03-28 | University Of Massachusetts | Procede d'induction de l'apoptose dans des cellules lymphoides |
WO2002071928A2 (fr) * | 2001-03-14 | 2002-09-19 | Millennium Pharmaceuticals, Inc. | Molecules d'acide nucleique et proteines destinees a l'identification, l'evaluation, la prevention et la therapie du cancer des ovaires |
WO2002102235A2 (fr) * | 2001-06-18 | 2002-12-27 | Eos Biotechnology Inc. | Procedes de diagnostic du cancer ovarien, compositions et procedes de criblage de modulateurs du cancer ovarien |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5627034A (en) * | 1995-12-05 | 1997-05-06 | Wisconsin Alumni Research Foundation | Assay for carcinoma proliferative status by measuring NGAL expression level |
EP1242598A2 (fr) * | 1999-12-30 | 2002-09-25 | Corixa Corporation | Composes pour l'immunotherapie et le diagnostic du cancer du colon et procedes d'utilisation |
-
2002
- 2002-07-02 DE DE10230631A patent/DE10230631A1/de not_active Withdrawn
-
2003
- 2003-06-12 AU AU2003245858A patent/AU2003245858A1/en not_active Abandoned
- 2003-06-12 WO PCT/DE2003/001986 patent/WO2004005540A2/fr not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998030907A1 (fr) * | 1997-01-06 | 1998-07-16 | Wisconsin Alumni Research Foundation | Dosage de detection immunohistochimique pour la determination de l'etat de proliferation d'un cancer |
WO1999053040A2 (fr) * | 1998-04-09 | 1999-10-21 | Metagen Gesellschaft Für Genomforschung Mbh | Sequences d'acide nucleique humain provenant de tissu de tumeur ovarienne |
WO2002024866A2 (fr) * | 2000-09-21 | 2002-03-28 | University Of Massachusetts | Procede d'induction de l'apoptose dans des cellules lymphoides |
WO2002071928A2 (fr) * | 2001-03-14 | 2002-09-19 | Millennium Pharmaceuticals, Inc. | Molecules d'acide nucleique et proteines destinees a l'identification, l'evaluation, la prevention et la therapie du cancer des ovaires |
WO2002102235A2 (fr) * | 2001-06-18 | 2002-12-27 | Eos Biotechnology Inc. | Procedes de diagnostic du cancer ovarien, compositions et procedes de criblage de modulateurs du cancer ovarien |
Non-Patent Citations (7)
Also Published As
Publication number | Publication date |
---|---|
WO2004005540A2 (fr) | 2004-01-15 |
AU2003245858A1 (en) | 2004-01-23 |
AU2003245858A8 (en) | 2004-01-23 |
DE10230631A1 (de) | 2004-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004030615A8 (fr) | Compositions et procedes de diagnostic et de traitement de tumeur | |
WO2004016225A8 (fr) | Compositions et methodes de diagnostic et de traitement des tumeurs | |
EP1571968A3 (fr) | Compositions et methodes permettant de diagnostiquer et de traiter une tumeur | |
WO2004045516A9 (fr) | Compositions et methodes pour le diagnostic et le traitement d'une tumeur | |
AU2003293460A1 (en) | Novel application of biosensors for diagnosis and treatment of disease | |
WO2003087831A3 (fr) | Proteines impliquees dans le cancer du sein | |
EP1572091A3 (fr) | Compositions et methodes de diagnostic et de traitement de tumeurs | |
WO2004060270A8 (fr) | Compositions et methodes pour diagnostiquer et traiter des tumeurs | |
EP1571968A4 (fr) | Compositions et methodes permettant de diagnostiquer et de traiter une tumeur | |
AU2003900747A0 (en) | Diagnosis and treatment of pancreatic cancer | |
ZA200409492B (en) | Compositions and methods for the diagnosis and treatment of tumor. | |
AU2002251844A1 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
WO2003057160A8 (fr) | Compositions et methodes de diagnostic et de traitement d'une tumeur | |
EP1572091A4 (fr) | Compositions et methodes de diagnostic et de traitement de tumeurs | |
AU2003300368A1 (en) | Methods and compositions for the diagnosis, prognosis, and treatment of cancer | |
ZA200500882B (en) | Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis of treatment or liver disorders and epithelial cancer | |
WO2005003154A8 (fr) | Compositions et methodes de diagnostic et de traitement de tumeur | |
AU2003904328A0 (en) | Diagnosis and treatment of neurodegenerative disorders | |
AU2003237792A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
WO2004005540A3 (fr) | Utilisations de substances qui se lient a ngal pour le diagnostic et le traitement de maladies cancereuses | |
AU2003294324A1 (en) | Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression | |
AU2003246592A1 (en) | Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases | |
WO2007048034A3 (fr) | Utilisation d'androgenes dans le traitement de la maladie de parkinson | |
AU2002346049A1 (en) | Coactivators in the diagnosis and treatment of breast cancer | |
WO2005052191A8 (fr) | Compositions et methodes de diagnostic et de traitement d'une tumeur |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |